- Home
- MDAI vs ALXO Comparison
MDAI vs ALXO Comparison
Compare MDAI & ALXO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MDAI
- ALXO
- Stock Information
- Founded
- MDAI 2013
- ALXO 2015
- Country
- MDAI United States
- ALXO United States
- Employees
- MDAI N/A
- ALXO N/A
- Industry
- MDAI Medical/Dental Instruments
- ALXO Biotechnology: Pharmaceutical Preparations
- Sector
- MDAI Health Care
- ALXO Health Care
- Exchange
- MDAI Nasdaq
- ALXO Nasdaq
- Market Cap
- MDAI 34.8M
- ALXO 24.0M
- IPO Year
- MDAI N/A
- ALXO 2020
- Fundamental
- Price
- MDAI $1.63
- ALXO $0.56
- Analyst Decision
- MDAI Strong Buy
- ALXO Strong Buy
- Analyst Count
- MDAI 2
- ALXO 6
- Target Price
- MDAI $4.75
- ALXO $3.30
- AVG Volume (30 Days)
- MDAI 276.1K
- ALXO 456.6K
- Earning Date
- MDAI 05-13-2025
- ALXO 05-08-2025
- Dividend Yield
- MDAI N/A
- ALXO N/A
- EPS Growth
- MDAI N/A
- ALXO N/A
- EPS
- MDAI N/A
- ALXO N/A
- Revenue
- MDAI $29,962,000.00
- ALXO N/A
- Revenue This Year
- MDAI N/A
- ALXO N/A
- Revenue Next Year
- MDAI $86.26
- ALXO N/A
- P/E Ratio
- MDAI N/A
- ALXO N/A
- Revenue Growth
- MDAI 55.21
- ALXO N/A
- 52 Week Low
- MDAI $0.82
- ALXO $0.41
- 52 Week High
- MDAI $3.25
- ALXO $10.97
- Technical
- Relative Strength Index (RSI)
- MDAI 65.66
- ALXO 59.08
- Support Level
- MDAI $1.57
- ALXO $0.44
- Resistance Level
- MDAI $1.73
- ALXO $0.48
- Average True Range (ATR)
- MDAI 0.10
- ALXO 0.05
- MACD
- MDAI 0.03
- ALXO 0.02
- Stochastic Oscillator
- MDAI 78.26
- ALXO 99.16
About MDAI Spectral AI Inc.
Spectral AI Inc is an AI company, focused on predictive medical diagnostics. Spectral is devoting substantially all of its efforts towards the research and development of its DeepView System, an internally developed MSI device that has designated FDA BDD status. Its DeepView System uses proprietary algorithms to distinguish between damaged and healthy human tissue invisible to the naked eye, providing Day One healing assessments in seconds. The Company's output is specifically engineered to allow the physician to make a more accurate, timely, and informed decision regarding the treatment of the patient's wound.
About ALXO ALX Oncology Holdings Inc.
ALX Oncology Holdings Inc is a clinical-stage immuno-oncology company focused on helping patients fight cancer by developing a pipeline of product candidates based on expertise in protein engineering and oncology led by the CD47 blocker, evorpacept, currently in phase 1 and 2 clinical trials. Cancer cells leverage CD47, a cell surface protein, as a don't eat me signal to evade detection by the immune system. The company is developing a next-generation checkpoint inhibitor designed to have a high affinity for CD47 and to avoid the limitations caused by hematologic toxicities inherent in other CD47 blocking approaches.